Loading…

Boiron SABOI.PACompetitor analysis, valuation and peers

France · EUR·Health Care›Pharmaceuticals: Other
Momentum laggard 12
Mkt cap
$367M
US dollars, full cap
Free float
13%
of shares outstanding
$/day
$69,356
20-day average traded
Fwd P/E
9.3×
forward earnings
ROIC−WACC
-1.0 pp
WACC 6.4%
Hurdle
-0 pp
Req g minus delivered
Next earnings
126 days
24 Mar 2027
Close · EUR€19.10
1D-0.8%
1W-0.8%
1M+6.1%
3M-26.8%
6M-31.3%
YTD-37.0%
1Y-28.2%
ATR %3.1%
52w lowhigh40.8% off high

What Boiron does

Employees: 2,634

Boiron at a glance

Size Boiron (BOI.PA) is a France Health Care company (Pharmaceuticals: Other) with a market value of $367M, the 194th largest of 206 France companies the cockpit tracks. Shares closed at €19.10 on 18 Nov 2026.

Performance Over six months the shares fell 31.3%, against -22.1% for the median peer and -2.1% for the France market (cap-weighted) — 4th lowest of 21 in its peer set.

Growth Revenue fell 1.8% over the last twelve months (peer median -4.0%); the operating margin is 5.2% (peer median 12.5%).

Valuation It trades at 9.3× forward earnings against a peer median of 16.2× (2nd cheapest of 8).

Price implies For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is -0 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 1.0 points below its cost of capital (6.4% WACC).

Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 79BOI.PA 68
Six months, rebased to 100: Boiron against the median of its 20 peers (local-currency closes).

Boiron financials

Reported figures in EUR; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue€496M€501M€488M€493M€534M
Revenue growth—+3%-1%-8%—
Gross profit€358M€366M€359M€358M€380M
EBITDA€56.7M€66.3M€65.8M€72.8M€87.7M
Net income€26.2M€32.6M€11.3M€35.8M€44.7M
Free cash flow€25.8M€40.2M€33.8M€42.3M€49.9M
Capital expenditure€26.2M€23.5M€15.9M€18.0M€18.6M
Total debtn/a€31.5M€15.0M€13.7M€22.2M

Quarterly statements and history in the cockpit →

Boiron competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-30%-20%-10%0%-20%0%778017070028263005198436317450603669002412002644AVBP07750025626004883007912877BOI.PA6-month return →1-month return →
Up and to the right = strong over both horizons. Boiron is the large dot.

Fundamentals: revenue growth against valuation

-20%-10%0%+10%+20%0×200×400×170784366031023015073002613007912877BOI.PARevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Boiron is the large dot.

Capital: growth delivered against growth the price implies

-20%-10%0%+10%+20%-20%0%20%17070028263005198436603102002412002644301507002562300039300791BOI.PAGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Boiron is the large dot.

Boiron competitors and peer comparison

How Boiron compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Boiron against its 20 peers (data as of 18 Nov 2026)
MeasureBOI.PAPeer medianRank in peer set
1-month return+6.1%-11.4%highest of 21
6-month return-31.3%-22.1%4th lowest of 21
Distance from 52-week high-40.8%-43.8%9th highest of 21
Revenue growth (TTM)-1.8%-4.0%9th highest of 19
Operating margin5.2%12.5%9th lowest of 21
Forward P/E9.3×16.2×2nd cheapest of 8
Growth the price implies (Req g, 7 yrs)-0.8%1.4%5th least demanding of 14
Growth delivered (Del g)-0.5%+5.6%4th lowest of 13
Hurdle (Req g minus delivered)-0.3 pp-2.9 pp5th most demanding of 13
ROIC minus cost of capital-1.0 pp+0.4 pp7th lowest of 20
EV / EBITDA5.4×4.6×2nd most expensive of 5
Net debt / EBITDA-0.5×-2.5×2nd most indebted of 7

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Boiron BOI.PAFrance$367M-31%-2%5%9.3×-0.8%-0.5%
Daiken Biomedical 7780.TWTaiwan$342M-19%n/a18%n/a-1.6%n/a
Grape King Bio 1707.TWTaiwan$342M-27%-5%19%9.7×-17.2%+2.3%
Tibet Aim Pharm 002826.SZChina$407M-22%+13%14%n/a0.4%+1.0%
Zhejiang Xinguang Pharmaceutical 300519.SZChina$319M-15%+5%27%n/a3.1%-1.3%
TCI 8436.TWOTaiwan$312M-24%-4%18%9.9×-12.1%-3.2%
Weihai Baihe Biology Technological 603102.SSChina$296M-22%+18%14%16.5×-11.8%+9.6%
Myung in Pharm 317450.KSSouth Korea$466M-20%+7%35%n/an/an/a
Lionco Pharmaceutical 603669.SSChina$474M+4%-6%-17%n/an/an/a
Hunan Hansen Pharmaceutical 002412.SZChina$532M-2%-4%21%n/a1.4%+7.0%
Lanzhou Foci Pharmaceutical 002644.SZChina$548M-9%+6%6%n/a15.4%+6.5%
ArriVent BioPharma AVBPUnited States$564M-60%n/a-3,620%n/an/an/a
Hangzhou Minsheng Healthcare 301507.SZChina$583M-23%+21%11%45.4×19.1%+12.1%
ABA Chemicals 300261.SZChina$592M-26%-16%-23%405.0×n/an/a
CK Life Sciences International (Holdings) 0775.HKHong Kong$613M-30%0%0%n/an/an/a
Shanxi Zhendong Pharmaceutical 300158.SZChina$641M-22%-28%-25%n/an/an/a
Brother Enterprises 002562.SZChina$668M-33%+8%4%n/a4.0%+13.5%
Shanghai Kaibao Pharmaceutical 300039.SZChina$703M-20%-14%22%n/a0.4%+4.8%
Tianjin Tianyao Pharmaceuticals 600488.SSChina$718M-36%-12%3%n/a2.1%-1.3%
Sirio Pharma 300791.SZChina$759M-6%-9%1%16.2×14.1%+15.6%
China Shineway Pharmaceutical 2877.HKHong Kong$760M-8%-18%25%7.6×n/an/a

Questions

Which companies are Boiron's closest peers?
The cockpit's peer set: Daiken Biomedical (7780.TW), Grape King Bio (1707.TW), Tibet Aim Pharm (002826.SZ), Zhejiang Xinguang Pharmaceutical (300519.SZ), TCI (8436.TWO), Weihai Baihe Biology Technological (603102.SS), Myung in Pharm (317450.KS), Lionco Pharmaceutical (603669.SS).
Is Boiron expensive compared with its peers?
On forward p/e it trades at 9.3× against a peer median of 16.2×, 2nd cheapest of 8 in its peer set. For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is -0 pp: the price already allows for a slowdown.
How has Boiron stock performed?
Over six months to 18 Nov 2026 the shares returned -31.3% against -22.1% for the median peer; over one year -28.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.